PureTech Health (GB:PRTC) has released an update.
Seaport Therapeutics, under the umbrella of PureTech Health, has enhanced its board by appointing David Wheadon, M.D., a seasoned pharmaceutical executive with a rich background in regulatory affairs and clinical development from companies like AstraZeneca and Eli Lilly. Dr. Wheadon’s expertise is expected to be pivotal in advancing Seaport’s pipeline of neuropsychiatric treatments for conditions such as depression and anxiety. This strategic move signals Seaport’s commitment to innovation and excellence in the development of new therapies for mental health disorders.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
